Corline Biomedical AB (CLBIO.ST)
SEK 8.76
(5.29%)
SEK 8.76
(5.29%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 100.1 Million SEK | -1.65% |
| 2022 | 101.78 Million SEK | 0.12% |
| 2021 | 101.66 Million SEK | 74.43% |
| 2020 | 58.28 Million SEK | -8.58% |
| 2019 | 63.75 Million SEK | 1.33% |
| 2018 | 62.91 Million SEK | 22.34% |
| 2017 | 51.42 Million SEK | 24.6% |
| 2016 | 41.27 Million SEK | 65.13% |
| 2015 | 24.99 Million SEK | 49.02% |
| 2014 | 16.77 Million SEK | 21.92% |
| 2013 | 13.75 Million SEK | 10.41% |
| 2012 | 12.46 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 101.07 Million SEK | -0.11% |
| 2024 Q1 | 101.18 Million SEK | 1.08% |
| 2023 Q1 | 103.44 Million SEK | 1.63% |
| 2023 Q3 | 99.35 Million SEK | -2.47% |
| 2023 Q4 | 100.1 Million SEK | 0.76% |
| 2023 FY | 100.1 Million SEK | -1.65% |
| 2023 Q2 | 101.86 Million SEK | -1.52% |
| 2022 Q1 | 97.29 Million SEK | -4.29% |
| 2022 Q4 | 101.78 Million SEK | -0.06% |
| 2022 Q3 | 101.84 Million SEK | 2.61% |
| 2022 FY | 101.78 Million SEK | 0.12% |
| 2022 Q2 | 99.25 Million SEK | 2.02% |
| 2021 FY | 101.66 Million SEK | 74.43% |
| 2021 Q3 | 97.29 Million SEK | -2.69% |
| 2021 Q4 | 101.66 Million SEK | 4.49% |
| 2021 Q1 | 70.19 Million SEK | 20.44% |
| 2021 Q2 | 99.98 Million SEK | 42.44% |
| 2020 Q1 | 62.08 Million SEK | -2.61% |
| 2020 FY | 58.28 Million SEK | -8.58% |
| 2020 Q3 | 57.08 Million SEK | -6.08% |
| 2020 Q4 | 58.28 Million SEK | 2.1% |
| 2020 Q2 | 60.77 Million SEK | -2.1% |
| 2019 Q2 | 69.65 Million SEK | 20.08% |
| 2019 FY | 63.75 Million SEK | 1.33% |
| 2019 Q4 | 63.75 Million SEK | -3.5% |
| 2019 Q3 | 66.06 Million SEK | -5.16% |
| 2019 Q1 | 58 Million SEK | -7.8% |
| 2018 Q2 | 62.07 Million SEK | 31.1% |
| 2018 Q3 | 65.23 Million SEK | 5.1% |
| 2018 Q4 | 62.91 Million SEK | -3.56% |
| 2018 FY | 62.91 Million SEK | 22.34% |
| 2018 Q1 | 47.34 Million SEK | -7.94% |
| 2017 Q3 | 55.2 Million SEK | 26.68% |
| 2017 Q2 | 43.58 Million SEK | -9.68% |
| 2017 Q1 | 48.25 Million SEK | 16.9% |
| 2017 Q4 | 51.42 Million SEK | -6.85% |
| 2017 FY | 51.42 Million SEK | 24.6% |
| 2016 FY | 41.27 Million SEK | 65.13% |
| 2016 Q4 | 41.27 Million SEK | -5.16% |
| 2016 Q3 | 43.51 Million SEK | -5.4% |
| 2016 Q2 | 46 Million SEK | 94.07% |
| 2016 Q1 | 23.7 Million SEK | -5.16% |
| 2015 Q4 | 24.99 Million SEK | -4.21% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q3 | 26.09 Million SEK | -4.75% |
| 2015 Q2 | 27.39 Million SEK | 0.0% |
| 2015 FY | 24.99 Million SEK | 49.02% |
| 2014 FY | 16.77 Million SEK | 21.92% |
| 2014 Q4 | 16.77 Million SEK | 0.0% |
| 2013 FY | 13.75 Million SEK | 10.41% |
| 2012 FY | 12.46 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 15.488% |
| Ziccum AB (publ) | 14.97 Million SEK | -568.615% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -399.501% |
| BioArctic AB (publ) | 1.18 Billion SEK | 91.56% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -60.484% |
| Mendus AB (publ) | 755.95 Million SEK | 86.758% |
| Genovis AB (publ.) | 288.85 Million SEK | 65.344% |
| Intervacc AB (publ) | 259.61 Million SEK | 61.44% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -138.578% |
| Active Biotech AB (publ) | 44 Million SEK | -127.511% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 64.087% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -61.065% |
| Aptahem AB (publ) | 63.02 Million SEK | -58.834% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 79.828% |
| Kancera AB (publ) | 65.64 Million SEK | -52.499% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 71.507% |
| Fluicell AB (publ) | 9.34 Million SEK | -971.788% |
| Saniona AB (publ) | 64.14 Million SEK | -56.065% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -197.914% |
| Biovica International AB (publ) | 131.4 Million SEK | 23.821% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -88.931% |
| AcouSort AB (publ) | 34.51 Million SEK | -190.05% |
| Xintela AB (publ) | 18.39 Million SEK | -444.197% |
| Abliva AB (publ) | 87.49 Million SEK | -14.407% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 86.832% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 92.045% |
| OncoZenge AB (publ) | 20.34 Million SEK | -392.158% |
| Amniotics AB (publ) | 26.08 Million SEK | -283.75% |
| 2cureX AB (publ) | 16.62 Million SEK | -502.135% |
| CombiGene AB (publ) | 120.61 Million SEK | 17.002% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -1547.277% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 94.733% |
| Camurus AB (publ) | 1.9 Billion SEK | 94.753% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 43.482% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 28.8% |
| I-Tech AB | 152.44 Million SEK | 34.333% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 90.167% |
| Cyxone AB (publ) | 43.65 Million SEK | -129.309% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -27.211% |
| Biosergen AB | 7.2 Million SEK | -1290.154% |
| Cantargia AB (publ) | 223.71 Million SEK | 55.253% |
| NextCell Pharma AB | 81.28 Million SEK | -23.149% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 86.919% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -231.77% |
| Nanologica AB (publ) | 77.42 Million SEK | -29.286% |
| SynAct Pharma AB | 228.01 Million SEK | 56.098% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -274.043% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -361.252% |
| LIDDS AB (publ) | 17.65 Million SEK | -467.007% |
| Lipum AB (publ) | 12.11 Million SEK | -726.631% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 92.851% |
| Alzinova AB (publ) | 123.18 Million SEK | 18.739% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 58.006% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -1083.974% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -17.457% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -573.246% |
| Simris Alg AB (publ) | 174.55 Million SEK | 42.65% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 53.877% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 84.682% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -14.968% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -251.147% |